Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Subst Use Misuse. 2011;46(2-3):218–232. doi: 10.3109/10826084.2011.522840

TABLE 2.

Baseline characteristics and 3-month follow-up data among 106 individuals enrolled in the STAR Program

Baseline n (%) 3-month follow-up n (%)
Baseline characteristics
 Male 53 (50.0)
 Race
  Hispanic 60 (56.6)
  Black 36 (34.4)
  Other 10 (9.4)
 HIV-infected for >3 years 100 (94.3)
 Medicaid 104 (98.1)
 Exposure to HIV
  MSM 4 (3.8)
  IDU 51 (49.0)
  MSM and IDU 1 (1.0)
  Sex with intravenous drug user 13 (12.6)
  Heterosexual sex (other than with intravenous drug user) 22 (21.2)
  Blood/blood product transfusion 3 (2.9)
HIV clinical outcomes
 Median log HIV viral load 3.7 3.2*
 Median CD4 count (cells/mm3) 276.0 275.5
Antiretroviral adherence
 Missed any doses in past 3 days 24 (30.8) 15 (18.5)
 Missed any doses in past week 32 (42.1) 23 (28.0)
Well-being in past week
 Depressed 64 (61.0) 51 (51.0)
 Everything was an effort 60 (57.7) 59 (59.0)
 Difficulty sleeping 73 (69.5) 60 (60.0)
 Unhappy 64 (61.0) 52 (52.0)
 Lonely 51 (48.6) 41 (41.0)
 Didn’t enjoy life 47 (45.2) 29 (29.0)*
 Sad 78 (74.3) 58 (58.0)*
 Could not get going 53 (51.5) 45 (45.0)
 Mean number of symptoms of depression (from list above) 5.0 4.0*
Drug use in past 3 months
 Cocaine 35 (33.7) 22 (22.2)
 Crack 17 (16.2) 15 (15.0)
 Heroin 9 (8.6) 7 (7.0)
 Street or club drugs (crystal meth, ecstasy, special k) 4 (3.8) 2 (2.0)
 Pain pills or benzodiazepines not prescribed 16 (15.7) 6 (6.0)*
 Regularly three or more alcoholic drinks a day 17 (16.7) 12 (12.0)

Note: The sample size does not total 106 in every analysis because of some missing data points. MSM = men who have sex with men and IDU = intravenous drug use.

*

p < .05.